Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 07, 2023

Type II RAF Inhibitor Tovorafenib for Relapsed/Refractory Pediatric Low-Grade Glioma

Nature Medicine


Additional Info

Nature Medicine
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
Nat. Med. 2023 Nov 17;[EPub Ahead of Print], LB Kilburn, DA Khuong-Quang, JR Hansford, D Landi, J van der Lugt, SES Leary, PH Driever, S Bailey, S Perreault, G McCowage, AJ Waanders, DS Ziegler, O Witt, PA Baxter, HJ Kang, TE Hassall, JW Han, D Hargrave, AT Franson, M Yalon Oren, H Toledano, V Larouche, C Kline, MS Abdelbaki, N Jabado, NG Gottardo, NU Gerber, NS Whipple, D Segal, SN Chi, L Oren, EEK Tan, S Mueller, I Cornelio, L McLeod, X Zhao, A Walter, D Da Costa, P Manley, SC Blackman, RJ Packer, K Nysom

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading